1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
Dermatophytosis Global Clinical Trials Review, H2, 2017

Clinical Research in Dermatophytosis in H2, 2017

  • July 2017
  • 87 pages
  • ID: 2506001
In this report:
Prospective, Double-blind, Randomized, Placebo-Controlled Phase III Study Evaluating Efficacy and Safety of Octagam ##% in Patients with Dermatomyositis (ProDERM Trial) Study Evaluating Efficacy and Safety of Octagam ##% in Patients with Dermatomyositis (Idiopathic Inflammatory Myopathy) (IIM) GDCT## NCT##, GAM##-##;2016-##-##;EudraCT-2016-##-##;## Musculoskeletal Disorders Dermatomyositis, Polymyositis/Idiopathic Inflammatory Myopathy Ongoing, recruiting Phase III Interventional immune globulin (human) Octapharma AG ## Dec 2016 ## Feb 2017 ## Mar 2019 ## ## ##

Summary

Table of Contents

Search Inside

Dermatophytosis Global Clinical Trials Review, H2, 2017

Brief

GlobalData's clinical trial report, "Dermatophytosis Global Clinical Trials Review, H2, 2017" offers an overview of Dermatophytosis clinical trials scenario. This industry report offers best line data relating to the clinical trials on Dermatophytosis. Report includes an overview of trial numbers and their average enrollment in most important countries conducted across the world. The market research affords coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also offers important drugs for in-progress trials. GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ distinct clinical trial registries, conferences, journals, news etc across the world. Clinical trials database undergoes periodic update by dynamic process.

The industry report enhances the decision making capabilities and helps to create an effective counter strategies to obtain competitive edge.

*Note: Certain parts in the study may be modified or deleted based on the availability and relevance of data for the indicated disease.

Overview

- The analysis offers a snapshot of the overall clinical trials landscape

- Report offers best level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status

- The market research reviews most important companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company

- The industry report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment

- The study offers enrollment trends for the past five years

- Report offers recent news for the past three months

*Note: Certain parts in the analysis may be modified or deleted based on the availability and relevance of data for the indicated disease.

Great reasons to purchase

- Assists in formulating top business strategies with regards to investment

- Helps in identifying main locations for conducting clinical trials which saves time and cost

- Offers best level analysis of Global Clinical Trials Market which helps in identifying main business opportunities

- Supports understanding of trials count and enrollment trends by country in overall therapeutics market

- Aids in interpreting the success rates of clinical trials by providing a comparable scenario of completed and uncompleted trials

- Facilitates clinical trial assessment of the indication on a overall, regional and country level

*Note: Certain parts in the market research may be modified or deleted based on the availability and relevance of data for the indicated disease.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Amrita helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Hidradenitis Suppurativa Global Clinical Trials Review, H2, 2017

Clinical Research in Hidradenitis Suppurativa in H2, 2017

  • $ 2500
  • Industry report
  • September 2017
  • by GlobalData

Hidradenitis Suppurativa Global Clinical Trials Review, H2, 2017SummaryGlobalData’s clinical trial report, “Hidradenitis Suppurativa Global Clinical Trials Review, H2, 2017" provides an overview of ...

Giant Cell Arteritis Global Clinical Trials Review, H2, 2017

Clinical Research in Giant Cell Arteritis in H2, 2017

  • $ 2500
  • Industry report
  • August 2017
  • by GlobalData

Giant Cell Arteritis Global Clinical Trials Review, H2, 2017SummaryGlobalData’s clinical trial report, “Giant Cell Arteritis Global Clinical Trials Review, H2, 2017" provides an overview of Giant Cell ...

Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) Global Clinical Trials Review, H2, 2017

Clinical Research in Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) in H2, 2017

  • $ 2500
  • Industry report
  • October 2017
  • by GlobalData

Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) Global Clinical Trials Review, H2, 2017SummaryGlobalData’s clinical trial report, “Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) ...


ref:plp2017

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.